Incyte (INCY) Income Statement Flow — TTM through Q2 2026
Calculated from the four most recent reported quarters, ending (reported ).
Incyte (INCY) Revenue by Product Segment — TTM through Q2 2026
Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.
| Segment | Revenue (USD) | % of total |
|---|---|---|
| J A K A F I | $3.83B | 65.8% |
| OPZELURA | $1.03B | 17.7% |
| M I N J U V I | $195M | 3.3% |
| Milestone And Contract Revenue | $180M | 3.1% |
| Olumiant Royalty | $162M | 2.8% |
| ZYNYZ | $152M | 2.6% |
| I C L U S I G | $148M | 2.5% |
| PEMAZYRE Royalty Revenues | $95.9M | 1.6% |
| Other segments | $27.4M | 0.5% |
| Total | $5.82B | 100% |
- J A K A F I$3.83B
- OPZELURA$1.03B
- M I N J U V I$195M
- Milestone And Contract Revenue$180M
- Olumiant Royalty$162M
- ZYNYZ$152M
- I C L U S I G$148M
- PEMAZYRE Royalty Revenues$95.9M
- Other segments$27.4M
- Total$5.82B
Incyte (INCY) Revenue by Geography — TTM through Q2 2026
Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.
| Region | Revenue (USD) | % of total |
|---|---|---|
| U [S] | $5.42B | 93.5% |
| Europe | $374M | 6.5% |
| Total | $5.79B | 100% |
- U [S]
- Europe
- Total
Revenue Breakdown — TTM through Q2 2026
In TTM through Q2 2026, Incyte (INCY) reports revenue across 9 reportable product segments; the largest segment was J A K A F I at 65.8%, followed by OPZELURA (17.7%) and M I N J U V I (3.3%). Geographically, U [S] accounted for 93.5% of revenue, followed by Europe (6.5%).
Frequently asked questions
Data & methodology
Incyte (INCY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.